

**PACE/PAP/CRDP
Provider Bulletin
Feb 16, 2023**

**Commonwealth of Pennsylvania
Drug Manufacturers' Rebate Program
Non-Participating Manufacturers**

Effective March 27, 2023, PACE, PAP and CRDP will no longer reimburse for all products from the labelers listed below for failing to comply with the Commonwealth's rebate program.

Providers using products from these manufacturers may wish to explore alternative sources.

Labeler Number	Drug Manufacturer Name	Medication(s) Affected
15370	Carwin Pharmaceuticals	RyVent™
42494	Cameron Pharmaceuticals	hydrocortisone suppository
47335	Sun Pharmaceuticals	albuterol, budesonide
50261	Therapeutics MD	Imvexxy ^(R)
50474	UCB Inc	Neupro ^(R) , Keppra ^(R)
51285	TEVA Women's Health	Trexall ^(R)
51862	Mayne Pharmaceutical	fluorouracil, clonidine
54838	Lannett Company	haloperidol concentrate
59917	Adare Pharmaceuticals	potassium chloride
62175	Lannett Company	omeprazole, pantoprazole
68047	Larken Laboratories	Oscimin SL
68308	Mayne Pharma	Nystatin 100,000 unit/gm powder
68645	Legacy Pharmaceutical	hydrochlorothiazide, lisinopril
69367	Westminster	hydrocortisone, celecoxib
69918	Amring Pharmaceutical	timolol maleate 0.5%
70594	Xellia Pharmaceuticals	vancomycin
71093	ACI Healthcare	gabapentin, metformin

Please direct any questions concerning this non-compliance decision to the appropriate manufacturer.